<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Cell. Neurosci.</journal-id>
<journal-title>Frontiers in Cellular Neuroscience</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Cell. Neurosci.</abbrev-journal-title>
<issn pub-type="epub">1662-5102</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fncel.2018.00504</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neuroscience</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>IRAK-M Deficiency Exacerbates Ischemic Neurovascular Injuries in Experimental Stroke Mice</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Lyu</surname> <given-names>Chenfei</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/603469/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhang</surname> <given-names>Yongfang</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gu</surname> <given-names>Minhua</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Huang</surname> <given-names>Yusheng</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Liu</surname> <given-names>Guanghui</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Wang</surname> <given-names>Chen</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Li</surname> <given-names>Miaodan</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Chen</surname> <given-names>Shumin</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Pan</surname> <given-names>Suyue</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/418296/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Gu</surname> <given-names>Yong</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/336441/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Neurology, Nanfang Hospital, Southern Medical University</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country></aff>
<aff id="aff2"><sup>2</sup><institution>School of Chinese Medicine, Southern Medical University</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country></aff>
<aff id="aff3"><sup>3</sup><institution>Department of Spinal Surgery, Nanfang Hospital, Southern Medical University</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country></aff>
<aff id="aff4"><sup>4</sup><institution>Department of Encephalopathy, Hainan Provincial Hospital of Traditional Chinese Medicine</institution>, <addr-line>Haikou</addr-line>, <country>China</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Dirk M. Hermann, Universit&#x00E4;t Duisburg-Essen, Germany</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Hirokazu Ohtaki, Showa University, Japan; Samaneh Maysami, University of Manchester, United Kingdom</p></fn>
<corresp id="c001">&#x002A;Correspondence: Suyue Pan, <email>pansuyue82@126.com</email> Yong Gu, <email>yonggu@smu.edu.cn</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>21</day>
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>12</volume>
<elocation-id>504</elocation-id>
<history>
<date date-type="received">
<day>21</day>
<month>08</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>05</day>
<month>12</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2018 Lyu, Zhang, Gu, Huang, Liu, Wang, Li, Chen, Pan and Gu.</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder>Lyu, Zhang, Gu, Huang, Liu, Wang, Li, Chen, Pan and Gu</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<abstract>
<p><bold>Background:</bold> Innate immune response to neuronal death is one of the key events of the pathogenesis of ischemic brain injury. Interleukin-1 receptor-associated kinase (IRAK)-M, encoded by gene <italic>Irak3</italic>, negatively regulates toll-like receptor signaling by interacting with the MyD88&#x2013;IRAK-4&#x2013;IRAK-1 complex and blocking the phosphorylation and dissociation of IRAK-1. Its function in the ischemic stroke is unknown.</p>
<p><bold>Objective:</bold> This study aims to investigate whether IRAK-M deficiency could exacerbate neuroinflammation and neurovascular injuries during cerebral ischemia and reperfusion.</p>
<p><bold>Methods:</bold> Male C57BL/6 mice and <italic>Irak3</italic> knockout mice were subjected to 45 min of middle cerebral artery occlusion and 4 or 24 h of reperfusion. Transcription of <italic>Irak3</italic> gene was evaluated by quantitative real-time PCR (qRT-PCR). Then, infarct volume, neurological score, brain water content, and Evans blue leakage were compared between knock-out and wild-type mice after reperfusion. Through the observation of gross brain specimen after cerebral ischemia, the incidence of hemorrhage transformation was compared between KO and WT mice. To explore underlying signaling pathways involved in IRAK-M deficiency, major proinflammatory cytokines and NF-&#x03BA;B signaling were measured by qRT-PCR and Western blot.</p>
<p><bold>Results:</bold> The expression of IRAK-M peaked at 1 h after reperfusion, and then gradually decreased within the first 24 h, which was abolished by blocking the expression of hypoxia induced factor 1&#x03B1;. IRAK-M deficiency increased infarct volume, brain edema, the incidence of hemorrhage transformation, and the permeability of blood&#x2013;brain barrier. In addition, the NF-&#x03BA;B-mediated expressions of proinflammatory cytokines and the activation of microglia in the ipsilateral brain from knock-out mice were much higher than those in wild-type littermates.</p>
<p><bold>Conclusion:</bold> IRAK-M deletion exacerbates neurovascular damages which are related to the pronounced activation of NF-&#x03BA;B signaling and neuroinflammatory responses during cerebral ischemia-reperfusion in mice. Our study indicates that IRAK-M has neuroprotective effect and has potential to facilitate the development of new pharmaceuticals that reduce neurovascular complications.</p>
</abstract>
<kwd-group>
<kwd>cerebral ischemia</kwd>
<kwd>IRAK-M</kwd>
<kwd>blood&#x2013;brain barrier</kwd>
<kwd>proinflammatory cytokines</kwd>
<kwd>NF-&#x03BA;B</kwd>
</kwd-group>
<counts>
<fig-count count="8"/>
<table-count count="2"/>
<equation-count count="0"/>
<ref-count count="48"/>
<page-count count="14"/>
<word-count count="0"/>
</counts>
</article-meta>
</front>
<body>
<sec><title>Introduction</title>
<p>Stroke is one of the leading causes of death and disability worldwide. With the increasing aging of population, the stroke incidence rate is projected to increase. Although a complicated sequence of pathophysiological events is involved in the pathogenesis of ischemic stroke, accumulating evidence demonstrates that inflammatory response is one of the key events in the ischemic brain injury and may offer potential therapeutic target for stroke therapy (<xref ref-type="bibr" rid="B22">Lakhan et al., 2009</xref>; <xref ref-type="bibr" rid="B17">Iadecola and Anrather, 2011</xref>). At the beginning of the focal perfusion defect, shear stress, oxidative stress, and hypoxia initiate both adaptive and innate inflammatory response (<xref ref-type="bibr" rid="B16">Gu et al., 2014</xref>). In this process, rapidly activated resident immune cells release multiple cytokines, which are responsible for neuron necrosis and injuries to the supportive structures in the brain (<xref ref-type="bibr" rid="B11">Eltzschig and Eckle, 2011</xref>), leading to the brain lesion caused by ischemia.</p>
<p>In the acute phase of cerebral ischemia, the innate immune response is triggered after the recognition of danger-associated molecular patterns by PRRs on macrophage or microglia (<xref ref-type="bibr" rid="B13">Garcia-Bonilla et al., 2014</xref>; <xref ref-type="bibr" rid="B27">Liesz et al., 2015</xref>). TLRs, a crucial family of PRR, play pivotal roles in inflammation via the activation of NF-&#x03BA;B, type I interferon, and MAPK signaling pathways (<xref ref-type="bibr" rid="B1">Akira and Takeda, 2004</xref>; <xref ref-type="bibr" rid="B37">Tang et al., 2007</xref>; <xref ref-type="bibr" rid="B11">Eltzschig and Eckle, 2011</xref>). Among them, the activation of TLR4 enhances the neuroinflammation and enlarges infarct size in experimental stroke model (<xref ref-type="bibr" rid="B4">Caso et al., 2007</xref>; <xref ref-type="bibr" rid="B45">Zhao et al., 2018</xref>). MyD88-dependent signaling pathway plays a key role in TLR4-mediated neuroinflammation after cerebral ischemia reperfusion (<xref ref-type="bibr" rid="B12">Gao et al., 2009</xref>). After being recruited to the TIR domain of TLR4, MyD88 binds to interleukin receptor associated kinase (IRAK) family, which activates cascades of downstream kinases and contributes to the activation of NF-&#x03BA;B (<xref ref-type="bibr" rid="B9">Deng et al., 2000</xref>). Upon TLRs activation, microglial cells release multiple inflammatory factors including TNF-&#x03B1;, IL-1&#x03B2;, iNOS, COX-2, MMPs, and etc. Subsequently, these factors destroy BBB and neurovascular unit.</p>
<p>IRAK-M encoded by <italic>Irak3</italic> negatively regulates TLRs signaling and ameliorates the inflammatory tissue injury (<xref ref-type="bibr" rid="B21">Kobayashi et al., 2002</xref>). Upon TLR4 ligation, the recruitment and formation of MyD88-IRAK-4-IRAK-1 complex (also called Myddosome) leads to IRAK1 phosphorylation by IRAK4 and its dissociation from complex. The free phosphorylated IRAK1 then binds to TRAF6 and activates IKK and NF-&#x03BA;B-dependent proinflammatory signaling. IRAK-M interacts with Myddosome to prevent the phosphorylation and dissociation of IRAK-1, interrupts the formation of the IRAK1-TRAF6 complex, and inhibits the activation of NF-&#x03BA;B signaling (<xref ref-type="bibr" rid="B1">Akira and Takeda, 2004</xref>; <xref ref-type="bibr" rid="B29">Liu et al., 2008</xref>). In addition to the established IRAK1 dependent pathway, IRAK-M is also reported to prevent the NF-&#x03BA;B-inducing kinase (NIK)&#x2013;IKK &#x03B1;-mediated alternative NF-&#x03BA;B pathway (<xref ref-type="bibr" rid="B35">Su et al., 2009</xref>) and TLR7-induced MEKK 3-dependent second wave NF-&#x03BA;B activation (<xref ref-type="bibr" rid="B46">Zhou et al., 2013</xref>). IRAK-M not only plays a critical role in immune related diseases including chronic alcoholic liver disease (<xref ref-type="bibr" rid="B47">Zhou et al., 2016</xref>), inflammatory bowel diseases (<xref ref-type="bibr" rid="B41">Weersma et al., 2007</xref>), and allergic airway inflammation (<xref ref-type="bibr" rid="B31">Nechama et al., 2018</xref>), but is also associated with the ischemic tolerance in the model of liver (<xref ref-type="bibr" rid="B18">Izuishi et al., 2006</xref>) and myocardial ischemia-reperfusion injury (<xref ref-type="bibr" rid="B6">Chen et al., 2012</xref>). Our previous research demonstrated that TLR4/IRAK-M pathway is possibly involved in cerebral ischemic tolerance induced by recombinant high mobility group box 1 preconditioning (<xref ref-type="bibr" rid="B40">Wang et al., 2016</xref>). However, up to now, little is known about how to induce IRAK-M and its function in the brain.</p>
<p><italic>Irak3</italic> expression is induced by several transcription factors. HIF-1&#x03B1; is a master regulator in response to hypoxia and ischemia (<xref ref-type="bibr" rid="B5">Chavez and LaManna, 2002</xref>), and is reported to regulate IRAK-M expression in monocytes in response to Lipid A (LPA, a specific TLR4 ligand) (<xref ref-type="bibr" rid="B33">Shalova et al., 2015</xref>). In the present study, we found that ischemia-induced HIF-1&#x03B1; is involved in the transcription of <italic>Irak3</italic>. Then we used <italic>Irak3</italic>-null mice for the first time to investigate the role of IRAK-M in cerebral ischemia, and found IRAK-M deficiency increased infarct volume, brain edema, incidence of hemorrhage transformation, BBB permeability, and levels of inflammatory responses.</p>
</sec>
<sec id="s1" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec><title>Animals</title>
<p><italic>Irak3</italic> KO mice on C57BL/6 background were obtained from Jackson Laboratories (Bar Harbor, ME, United States, <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:IMSR_JAX:007016">RRID:IMSR_JAX:007016</ext-link>) and WT littermates were generated through heterozygous mating. Mice were housed in a SPF environment with a 12 h light/dark cycle and a temperature of (22 &#x00B1; 1&#x00B0;C) and were offered free access to food and water. <italic>Irak3</italic> deficient mice developed severe osteoporosis (<xref ref-type="bibr" rid="B25">Li et al., 2005</xref>), increased inflammatory responses to bacterial infection (<xref ref-type="bibr" rid="B21">Kobayashi et al., 2002</xref>), promoted adverse remodeling and worse systolic dysfunction in myocardial infarction (<xref ref-type="bibr" rid="B6">Chen et al., 2012</xref>), and enhanced the development of type 1 diabetes in NOD mice (<xref ref-type="bibr" rid="B36">Tan et al., 2014</xref>). DNA of WT and KO mice was extracted from mouse tails with a genomic DNA kit (CoWin Biotech, Beijing, China). To confirm the genotype of mice, extracted DNA was amplified by DNA polymerase (Takara, Kusatsu, Japan) and then separated by agarose gel. Male WT and KO mice (age 7&#x2013;10 weeks; weight 22&#x2013;26 g) were used for the experiments. Randomization was performed by a third person unrelated to the study using a randomization table. Animal experimental protocols were approved by the Animal Care and Use Committee of the Nanfang Hospital, Southern Medical University (NFYY-2017-42) and followed the National Guidelines for Animal Experimentation. All efforts were made to minimize the number of animals used and their suffering.</p>
</sec>
<sec><title>Transient Focal Brain Ischemia Reperfusion Model</title>
<p>Mouse tMCAO was produced by filament occlusion of the right MCA to induce transient focal brain ischemia-reperfusion. In the pre-experiment, we found that 1 h of tMCAO caused a very high mortality in <italic>Irak3</italic> KO mice. Therefore, we chose 45 min tMCAO to conduct following experiments. In brief, mice were anesthetized with isoflurane (induction with 4%; maintenance with 1.5%) in oxygen-enriched air by face mask, and murine temperature was maintained at 37 &#x00B1; 0.5&#x00B0;C throughout the experiment with heating pad. MCAO was performed by inserting a 7-0 nylon monofilament into the internal carotid artery via an external carotid artery stump and then by positioning the filament tip for occlusion at a distance of 8&#x2013;9 mm beyond the internal carotid/pterygopalatine artery bifurcation. MCA was occluded for 45 min followed by reperfusion. Regional CBF (rCBF) was measured by the laser Doppler blood flow assessment (Moor Instruments, Wilmington, DE, United States) and presented as percentage of basal level (Figure <xref ref-type="fig" rid="F1">1A</xref>). The blunt needle probe of the laser Doppler blood flow assessment was positioned on skull surface in the MCA territory (1 mm posterior to the Bregma, and 5 mm lateral to the midline on the right parietal skull). Regional CBF was detected at four time points: before and after tMCAO; before and after reperfusion. Mice that did not show a >75% rCBF reduction or a &#x003C;60% rCBF reperfusion over baseline levels or died after ischemia induction were excluded.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption><p>Interleukin-1 receptor-associated kinase (IRAK)-M was significantly increased after cerebral ischemia reperfusion. <bold>(A)</bold> Cerebral blood flow (CBF) of each mouse subjected to tMCAO detected by laser-Doppler and showed as percentage of basal level. <bold>(B)</bold> Relative mRNA levels of IRAK-M were measured by real-time RT-PCR at different time points after reperfusion in the infarcted cerebral hemisphere. Marked upregulation was noted after 1 and 8 h of reperfusion. <bold>(C</bold>,<bold>D)</bold> Effect of 2ME2 on the mRNA expression of HIF-1&#x03B1; <bold>(C)</bold> and IRAK-M <bold>(D)</bold> in the ipsilateral hemisphere at 1 h after reperfusion. Data are presented as mean &#x00B1; SD, <italic>n</italic> = 6 per group. <sup>&#x2217;</sup><italic>P</italic> &#x003C; 0.05, <sup>&#x2217;&#x2217;</sup><italic>P</italic> &#x003C; 0.01 vs. sham group.</p></caption>
<graphic xlink:href="fncel-12-00504-g001.tif"/>
</fig>
</sec>
<sec><title>Drug Administration</title>
<p>In order to study whether HIF-1&#x03B1; is associated with the expression of IRAK-M, WT mice were injected with 2-methoxyestradiol (2ME2) to suppress the expression of HIF-1&#x03B1;. Animals were randomly divided into different groups. The inhibitor of HIF-1&#x03B1;, 2-methoxyestradiol (2ME2, MedChemExpress, NJ, United States), was dissolved in dimethyl sulfoxide (DMSO) and further diluted in saline. 2ME2 solution was administered (5 mg/kg, i.p.) at 10 min before tMCAO. The WT mice in vehicle groups were intraperitoneally injected with same volume of DMSO diluted in saline.</p>
</sec>
<sec><title>Neurological Tests</title>
<p>At 24 h after reperfusion, the global neurological and motor function of the animals were assessed using a modified Bederson Score (Table <xref ref-type="table" rid="T1">1</xref>) and the grip test (string test) (<xref ref-type="bibr" rid="B10">Denorme et al., 2016</xref>) by a researcher blinded to group allocation. For the grip test, a length of string (50 cm) was pulled tight between two vertical supports and elevated 40 cm from a flat surface. The mouse was placed midway on the string and rated as shown in Table <xref ref-type="table" rid="T1">1</xref>.</p>
<table-wrap position="float" id="T1">
<label>Table 1</label>
<caption><p>Neurological function score.</p></caption>
<table cellspacing="5" cellpadding="5" frame="hsides" rules="groups">
<thead>
<tr>
<th valign="top" align="left">Score</th>
<th valign="top" align="left">A modified Bederson score</th>
<th valign="top" align="left">Score</th>
<th valign="top" align="left">The grip test</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">0</td>
<td valign="top" align="left">No deficit.</td>
<td valign="top" align="left">0</td>
<td valign="top" align="left">Falls off.</td></tr>
<tr>
<td valign="top" align="left">1</td>
<td valign="top" align="left">Forelimb flexion.</td>
<td valign="top" align="left">1</td>
<td valign="top" align="left">Hangs onto string by one or both forepaws.</td>
</tr>
<tr>
<td valign="top" align="left">2</td>
<td valign="top" align="left">As for 1, plus decreased resistance to lateral push.</td>
<td valign="top" align="left">2</td>
<td valign="top" align="left">As for 1, and attempts to climb onto string.</td>
</tr>
<tr>
<td valign="top" align="left">3</td>
<td valign="top" align="left">Unidirectional circling.</td>
<td valign="top" align="left">3</td>
<td valign="top" align="left">Hangs onto string by one or both forepaws plus one or both hind paws.</td>
</tr>
<tr>
<td valign="top" align="left">4</td>
<td valign="top" align="left">Longitudinal spinning or seizure activity.</td>
<td valign="top" align="left">4</td>
<td valign="top" align="left">Hangs onto string by fore and hind paws plus tail wrapped around string.</td>
</tr>
<tr>
<td valign="top" align="left">5</td>
<td valign="top" align="left">No movement.</td>
<td valign="top" align="left">5</td>
<td valign="top" align="left">Escape (to the supports).</td></tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec><title>Evaluation of Infarct Size and Hemispheric Brain Swelling</title>
<p>After 45 min of MCAO and 24 h of reperfusion, brain tissues at 1.0&#x2013;8.0 mm posterior to the frontal pole were sliced coronally at a thickness of 1 mm and stained with 1% TTC (Sigma-Aldrich, St Louis, MO, United States). Infarct volume was then measured with using ImageJ software (NIH, Bethesda, MD, United States) and presented as percentage of the total brain volume by an experimenter blinded to group allocation (<xref ref-type="bibr" rid="B40">Wang et al., 2016</xref>). Hemispheric brain swelling was quantified according to the brain sections with the equation: hemispheric brain swelling = (volume of ipsilateral hemisphere/volume of contralateral hemisphere &#x2013; 1) &#x00D7; 100%.</p>
</sec>
<sec><title>Evaluation of BBB Permeability and Water Content</title>
<p>To evaluate the integrity of the BBB, EB leakage and IgG immunohistochemistry were performed at 24 h after reperfusion. EB was injected to mice via femoral vein (2% in normal saline at 4 ml/kg). At 24 h after reperfusion, animals were anesthetized and perfused with PBS. Then, cerebral hemispheres were incubated in 10 ml of methanamide (Macklin, Shanghai, China) at 60&#x00B0;C for 24 h and centrifuged. The supernatant was taken for spectrophotometric quantification of extravasated EB dye at by spectrophotometer (BMG Labtech, Offenburg, Germany).</p>
<p>For water content assay brain tissues were weighed on an electronic analytical balance to get the wet weight, and were dried in an oven at 60&#x00B0;C for 7 days to obtain the dry weight. Brain tissue water content was measured by the weighing the brain at wet and dry state and was calculated as (wet weight &#x2013; dry weight)/wet weight &#x00D7; 100%.</p>
</sec>
<sec><title>Western Blot Analysis</title>
<p>Brain tissues from the same region (2.0&#x2013;4.0mm posterior to the frontal pole) were obtained with coronal cut, were divided into ipsilateral and contralateral hemispheres, and were homogenized in RIPA lysis buffer (Leagene, Beijing, China) containing protease and phosphatase inhibitors. After denatured in loading buffer, proteins were separated by SDS-PAGE (8&#x2013;10% acrylamide) and then transferred to polyvinylidene difluoride membranes (Millipore, Billerica, MA, United States). After blocked by 5% non-fat milk, the membranes were incubated overnight at 4&#x00B0;C with primary antibodies including anti-COX-2 (1:1000; CST, Beverly, MA, United States, <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_2571729">RRID:AB_2571729</ext-link>), anti-TNF-&#x03B1; (1:500; Santa Cruz; CA, United States, <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_1567355">RRID:AB_1567355</ext-link>), anti-IL-10 (1:500; Santa Cruz, <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_10859554">RRID:AB_10859554</ext-link>), anti-NLRP-3 (1:1000; NOVUS, CO, Cat# NBP2-12446), anti-iNOS (1:100; Santa Cruz, <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_627810">RRID:AB_627810</ext-link>), anti-p65 (1:1000; Proteintech, Chicago, IL, United States, <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_2178878">RRID:AB_2178878</ext-link>), anti-&#x03B2;-actin (1:1000; Proteintech, Chicago, IL, United States, <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_2289225">RRID:AB_2289225</ext-link>), and anti-TBP (1:500; Proteintech, <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_10951514">RRID:AB_10951514</ext-link>) followed by incubation with anti-rabbit or anti-mouse horseradish peroxidase-conjugated secondary antibodies (1:5000; Santa Cruz). Bands were detected by chemiluminescence technology with using enhanced chemiluminescence advance Western blotting detection reagents (FDbio, Hangzhou, China), quantified and normalized to &#x03B2;-actin using ImageJ by an experimenter blinded to group allocation. The pictures of protein bands were opened by ImageJ and maximized to an appropriate zoom level. A frame was drawn around each band to make the band in the center of frame. The densities of protein blots were measured by program in ImageJ. The final relative quantification values are the ratios of net target bands to net loading controls.</p>
</sec>
<sec><title>Histological Examination</title>
<p>Mice were perfused with saline and 4% paraformaldehyde at 24 h after reperfusion. Brains were post-fixed and subsequently immersed in 15% sucrose and 30% sucrose. Based on TTC stained and EB images, we selected the region at 4.0&#x2013;5.0 mm posterior to the frontal pole. Coronal brain sections were obtained by slicing with Cryostat Microtome (Leica CM1800, Heidelberg, Germany). To detect the BBB permeability, immunohistochemistry was conducted with antibodies against mouse IgG (CoWin Biotech, Beijing, China) in accordance with the protocol suggested by the supplier (<xref ref-type="bibr" rid="B28">Lin et al., 2017</xref>). One picture of immunohistochemistry was opened by ImageJ. Region of interest (ROI) was selected by H-DAB in select model mode. Then the IgG relative intensity was measured. The antibody against Iba1 was used to detect microglia. Cryosections were permeabilized with Triton X-100, and were blocked with donkey serum. Sections were incubated with primary antibody against Iba1 (1:100; Abcam, Cambridge, United Kingdom, <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_1141557">RRID:AB_1141557</ext-link>) overnight at 4&#x00B0;C and then with donkey anti-rabbit secondary antibody-conjugated to Alexa488 (1:500; Abcam) for 1 h at 37&#x00B0;C. Four serial sections of each brain sample were observed, three similar fields were selected in the brain region surrounded by three black boxes (Figure <xref ref-type="fig" rid="F8">8C</xref>) under an Olympus Fluorview laser scanning confocal microscope (Olympus, Tokyo, Japan). The number of Iba1-positive cells was counted by using ImageJ by an independent investigator who did not know the animal grouping (<xref ref-type="bibr" rid="B26">Li et al., 2018</xref>).</p>
</sec>
<sec><title>Quantitative Real-Time PCR</title>
<p>Brain tissues of the same region (2.0&#x2013;4.0mm posterior to the frontal pole) were obtained with coronal cut and were divided into ipsilateral and contralateral hemispheres. Total RNA of ipsilateral and contralateral hemispheres was isolated by using Trizol (Takara), and 1 &#x03BC;g of total RNA was reverse-transcribed to cDNA using PrimeScript<sup>TM</sup> RT Master Mix Kit (Takara). RT-qPCR was performed with Roche LightCycler480 System (Roche, Basel, Switzerland) by using SYBR Green master mixes (Takara). Quantification was performed by the delta cycle time method, with mouse &#x03B2;-actin used for normalization. The mouse-specific primers (Sangon Biotech, Shanghai, China) are listed in Table <xref ref-type="table" rid="T2">2</xref>.</p>
<table-wrap position="float" id="T2">
<label>Table 2</label>
<caption><p>Primers used for real-time PCR.</p></caption>
<table cellspacing="5" cellpadding="5" frame="hsides" rules="groups">
<thead>
<tr>
<th valign="top" align="left">Genes</th>
<th valign="top" align="left">Primer sequences</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">&#x03B2;-Actin</td>
<td valign="top" align="left">SENS: CGTTGACATCCGTAAAGACC</td>
</tr>
<tr>
<td valign="top" align="left">IRAK-M</td>
<td valign="top" align="left">REVS: AACAGTCCGCCTAGAAGCAC</td></tr>
<tr>
<td valign="top" align="left"></td>
<td valign="top" align="left">SENS: CAGGTGTCCTTCTCCACTGTTCTTG</td>
</tr>
<tr>
<td valign="top" align="left"></td>
<td valign="top" align="left">REVS: GTGACCTCAGACTGGCTGCA</td></tr>
<tr>
<td valign="top" align="left">MMP-2</td>
<td valign="top" align="left">SENS: TGGCACCACCGAGGACTATGAC</td>
</tr>
<tr>
<td valign="top" align="left"></td>
<td valign="top" align="left">REVS: ACACCACACCTTGCCATCGTTG</td></tr>
<tr>
<td valign="top" align="left">MMP-9</td>
<td valign="top" align="left">SENS: GGAGCACGGCAACGGAGAAG</td>
</tr>
<tr>
<td valign="top" align="left"></td>
<td valign="top" align="left">REVS: CCTGGTCATAGTTGGCTGTGGTG</td></tr>
<tr>
<td valign="top" align="left">IL-1&#x03B2;</td>
<td valign="top" align="left">SENS: TCGCAGCAGCACATCAACAAGAG</td>
</tr>
<tr>
<td valign="top" align="left"></td>
<td valign="top" align="left">REVS: TGCTCATGTCCTCATCCTGGAAGG</td></tr>
<tr>
<td valign="top" align="left">IL-6</td>
<td valign="top" align="left">SENS: ACTTCCATCCAGTTGCCTTCTTGG</td>
</tr>
<tr>
<td valign="top" align="left"></td>
<td valign="top" align="left">REVS: TTAAGCCTCCGACTTGTGAAGTGG</td></tr>
<tr>
<td valign="top" align="left">TNF-&#x03B1;</td>
<td valign="top" align="left">SENS: GCGACGTGGAACTGGCAGAAG</td>
</tr>
<tr>
<td valign="top" align="left"></td>
<td valign="top" align="left">REVS: GCCACAAGCAGGAATGAGAAGAGG</td></tr>
<tr>
<td valign="top" align="left">IL-10</td>
<td valign="top" align="left">SENS: CTGCTATGCTGCCTGCTCTTACTG</td>
</tr>
<tr>
<td valign="top" align="left"></td>
<td valign="top" align="left">REVS: ATGTGGCTCTGGCCGACTGG</td></tr>
<tr>
<td valign="top" align="left">COX-2</td>
<td valign="top" align="left">SENS: CTGGTGCCTGGTCTGATGATGTATG</td>
</tr>
<tr>
<td valign="top" align="left"></td>
<td valign="top" align="left">REVS: GGATGCTCCTGCTTGAGTATGTCG</td></tr>
<tr>
<td valign="top" align="left">iNOS</td>
<td valign="top" align="left">SENS: ATCTTGGAGCGAGTTGTGGATTGTC</td>
</tr>
<tr>
<td valign="top" align="left"></td>
<td valign="top" align="left">REVS:TCGTAATGTCCAGGAAGTAGGTGAGG</td></tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec><title>Statistical Analysis</title>
<p>Statistical analyses were conducted by using SPSS 20.0 (IBM, Armonk, NY, United States) and GraphPad Prism 5.0 (GraphPad, La Jolla, CA, United States). During experiments and analysis, the investigators were blinded to genotype and experimental group. Data points outside the 95% confidence interval were excluded from the data analysis. Comparison between two groups was performed by using a two-tailed <italic>t</italic>-test. Differences within multiple groups were examined by two-way ANOVA followed by the Bonferroni <italic>post hoc</italic> correction. The incidence of hemorrhagic transformation in two groups was compared by using a Chi-square test. Data were expressed as mean &#x00B1; SD. <italic>P</italic> &#x003C; 0.05 was considered as statistically significant.</p>
</sec>
</sec>
<sec><title>Results</title>
<sec><title>Cerebral Ischemia-Reperfusion Time-Dependently Induced IRAK-M Expression in Mice</title>
<p>To explore the response of IRAK-M expression to cerebral ischemia-reperfusion, we firstly conducted mouse model of tMCAO with different reperfusion time followed by determination of IRAK-M mRNA expression with real-time fluorescence quantitative PCR. Regional CBF (rCBF) of each mouse was measured and shown in Figure <xref ref-type="fig" rid="F1">1A</xref>. After MCA was occluded, CBF decreased from 190.10 &#x00B1; 17.02 to 28.03 &#x00B1; 10.25 IU. When the nylon monofilament was removed, CBF returned to 163.70 &#x00B1; 17.92 from 29.96 &#x00B1; 8.33 IU. Results showed that IRAK-M mRNA was significantly upregulated in the infarcted brain tissue. Moreover, its expression peaked at 1h after reperfusion, 23.53 &#x00B1; 13.27 folds higher than sham operative mice, and decreased to 18.79 &#x00B1; 7.33, 5.70 &#x00B1; 3.00 and 3.23 &#x00B1; 1.70 folds at 8, 12, 24 h after reperfusion (Figure <xref ref-type="fig" rid="F1">1B</xref>), suggesting the time-dependent response of IRAK-M expression in ischemia-reperfused mice.</p>
<p>Hypoxia-inducible factor 1&#x03B1; is a key transcription factor induced by cerebral ischemia (<xref ref-type="bibr" rid="B48">Zhu et al., 2014</xref>) and is possibly involved in the IRAK-M expression (<xref ref-type="bibr" rid="B33">Shalova et al., 2015</xref>). To investigate whether HIF1&#x03B1; was responsible for inducing IRAK-M upregulation after reperfusion, we inhibited HIF1&#x03B1; mRNA expression before tMCAO onset. The results displayed that 2ME2 markedly suppressed the expression of HIF-1&#x03B1; and IRAK-M at 1 h after brain ischemia compared with the vehicle treated group (Figures <xref ref-type="fig" rid="F1">1C,D</xref>), indicating that the increase of HIF-1&#x03B1; correlates with the upregulation of IRAK-M after cerebrovascular obstruction and reperfusion.</p>
</sec>
<sec><title>IRAK-M Deficiency Enlarged Infarct Volume and Deteriorated Motor Function After Cerebral Ischemia and Reperfusion in Mice</title>
<p>Next, IRAK-M KO mice were used to observe the role IRAK-M in stroke mice. We assessed the neurological deficits and infarct volume of the mice via neurological function score and TTC staining, respectively, at 24 h after cerebral ischemia. Eleven mice were employed in both KO and WT groups to carefully observe the neurological outcome. Results showed that the deficiency of the IRAK-M led to a larger brain infarct volume (Figures <xref ref-type="fig" rid="F2">2A,D</xref>, <italic>P</italic> &#x003C; 0.05 vs. WT) and deteriorated motor function deficit, including higher Bederson score and lower grip test score (Figures <xref ref-type="fig" rid="F2">2B,C</xref>, <italic>P</italic> &#x003C; 0.05 vs. WT) compared with WT controls. We also observed hemispheric swelling on the basis of Figure <xref ref-type="fig" rid="F2">2A</xref>, and the data showed that the genetic deletion of IRAK-M significantly increased hemispheric swelling (Figure <xref ref-type="fig" rid="F2">2E</xref>, <italic>P</italic> &#x003C; 0.05 vs. WT). These results demonstrate that IRAK-M deletion increases the infarct volume, and deteriorates the motor function of stroke mice.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption><p><italic>Irak3</italic>-null mice exhibited larger infarct volume and higher swelling index. <bold>(A)</bold> Representative images of TTC-stained brain slices from gene knockout and wild-type (WT) mice. <bold>(B,C)</bold> Neurologic deficit scores in WT and KO mice at 24 h after reperfusion. <bold>(D,</bold> <bold>E)</bold> Infarct size and swelling index were calculated with ImageJ software according to TTC staining. Data are presented as mean &#x00B1; SD, <italic>n</italic> = 11 per group. <sup>&#x2217;</sup><italic>P</italic> &#x003C; 0.05, <sup>&#x2217;&#x2217;</sup><italic>P</italic> &#x003C; 0.01 vs. WT group.</p></caption>
<graphic xlink:href="fncel-12-00504-g002.tif"/>
</fig>
</sec>
<sec><title>IRAK-M Deficiency Exacerbated Brain Edema and Hemorrhagic Transformation in Mice Model of Stroke</title>
<p>Based on the increased swelling index and the observed severe edema (Figure <xref ref-type="fig" rid="F3">3A</xref>) in KO mice, we further examined the effect of IRAK-M KO on water content in mouse brain subjected to tMCAO. Data revealed that, after 24 h of reperfusion, brain water content from ischemic KO mice was remarkably more than that in WT littermates (78.98 &#x00B1; 0.87 vs. 77.22 &#x00B1; 0.59, <italic>P</italic> &#x003C; 0.05, Figures <xref ref-type="fig" rid="F3">3A,B</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption><p><italic>Irak3</italic> knockout increased brain water content and the incidence of cerebral hemorrhage transformation after reperfusion. <bold>(A)</bold> After 45 min tMCAO and 24h reperfusion, brains were isolated and photographs showing brain edema was captured. <bold>(B)</bold> Water content was measured by wet/dry method. Cerebral ischemia resulted in a marked increment in water content. IRAK-M deficiency accentuated brain swelling in MCAO mice compared with WT group. Data are expressed as mean &#x00B1; SD, <italic>n</italic> = 6 per group. <bold>(C)</bold> Representative photographs showing the visible hemorrhagic foci appeared on the infarcted brain of the KO mice. <bold>(D)</bold> The incidence of cerebral hemorrhage transformation in each group was calculated. <italic>n</italic> = 31 in KO group and <italic>n</italic> = 25 in WT group. <sup>&#x2217;</sup><italic>P</italic> &#x003C; 0.05 vs. WT group, <sup>#</sup><italic>P</italic> &#x003C; 0.05 vs. sham group.</p></caption>
<graphic xlink:href="fncel-12-00504-g003.tif"/>
</fig>
<p>During the process of brain isolation, the obvious hemorrhagic foci were found in KO mice (Figure <xref ref-type="fig" rid="F3">3C</xref>). Therefore, the incidence of visible hemorrhagic transformation was calculated among all included stroke mice. Twelve of the 31 KO mice developed visible hemorrhagic transformation after cerebral ischemia. In contrast, only two out of the 25 WT mice had intracerebral hemorrhage, much less than that in KO mice. In other word, IRAK-M deficiency remarkably increased the incidence of hemorrhagic transformation after cerebral ischemia-reperfusion (37.05% vs. 8.70%, <italic>P</italic> &#x003C; 0.05, Figure <xref ref-type="fig" rid="F3">3D</xref>).</p>
</sec>
<sec><title>IRAK-M Deficiency Increased BBB Permeability in Mice</title>
<p>More remarkable brain edema and visible hemorrhagic foci in IRAK-M KO mice indicate more severe BBB leakage. Thus, temporal changes in BBB integrity were assessed by EB extravasation and IgG leakage after focal ischemic insult. As expected, EB leakage assay showed that the dye content in ipsilateral ischemic hemispheres was obviously higher in KO group than that in WT group (<italic>P</italic> &#x003C; 0.05, Figures <xref ref-type="fig" rid="F4">4A,B</xref>), whereas no difference was found in contralateral hemispheres.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption><p>IRAK-M deficiency accentuated the extent of blood&#x2013;brain barrier (BBB) leakage in mice. <bold>(A,</bold> <bold>B)</bold> Photographs and quantification of Evans blue extravasation are shown. Evans blue staining reveals an increase in the extent of BBB disruption in KO mice 24 h after reperfusion compared with that in WT mice. <bold>(C)</bold> Representative photomicrographs of IgG leakage in hippocampus and cortex at 24 h after reperfusion, respectively. Bar, 100 &#x03BC;m. <bold>(D)</bold> Representative microscopic images of brain sections after IgG staining. Bar, 800 &#x03BC;m. <bold>(E)</bold> The IgG relatively intensity was calculated with ImageJ and presented in the bar graphs. Data are expressed as mean &#x00B1; SD, <italic>n</italic> = 6 per group. <sup>&#x2217;</sup><italic>P</italic> &#x003C; 0.05, <sup>&#x2217;&#x2217;</sup><italic>P</italic> &#x003C; 0.01 vs. WT group, <sup>#</sup><italic>P</italic> &#x003C; 0.05 vs. sham group.</p></caption>
<graphic xlink:href="fncel-12-00504-g004.tif"/>
</fig>
<p>Moreover, endogenous IgG immunohistochemistry showing its extravasation in the brain was conducted as another approach to examine the location of BBB disruption. As shown in Figures <xref ref-type="fig" rid="F4">4C,D</xref>, ischemia reperfusion markedly increased IgG staining both in cortex and hippocampus of the ipsilateral hemispheres. Consistently, IRAK-M deficiency strikingly increased relative intensity of IgG staining in cortex and hippocampus (Figures <xref ref-type="fig" rid="F4">4C</xref>&#x2013;<xref ref-type="fig" rid="F4">F</xref>).</p>
<p>We next studied the potential mechanisms underlying the deteriorated BBB disruption after the deletion of IRAK-M. According to the Figures <xref ref-type="fig" rid="F5">5A</xref>&#x2013;<xref ref-type="fig" rid="F5">D</xref>, mRNA expression levels of MMP-2 and MMP-9 were robustly elevated in the injured brain tissue of KO group compared with WT group at 4 h after brain ischemia. After 24 h reperfusion, MMP-9, but not MMP-2, mRNA level increased in the ischemic cortex of KO mice compared with those of WT mice. Together, genetic deletion of IRAK-M accentuated BBB disruption via the upregulated expression of MMP-2 and MMP-9 in the mouse model of ischemic stroke.</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption><p>MMP-2 and MMP-9 expression were increased in the ischemic brain of KO mice. <bold>(A</bold>&#x2013;<bold>D)</bold> Bar graphs and linear graphs showing the mRNA levels of MMP-2 <bold>(A,B)</bold> and MMP-9 <bold>(C,D)</bold> in ipsilateral and contralateral hemisphere of cerebral ischemia. The IgG relative intensity was measured using ImageJ. Data are expressed as mean &#x00B1; SD, <italic>n</italic> = 6 mice per group. <sup>&#x2217;&#x2217;</sup><italic>P</italic> &#x003C; 0.01 vs. WT group, <sup>#</sup><italic>P</italic> &#x003C; 0.05 vs. sham group.</p></caption>
<graphic xlink:href="fncel-12-00504-g005.tif"/>
</fig>
</sec>
<sec><title>Reduction of IRAK-M Triggered Expression of Proinflammatory Factors in Mouse Brain After Cerebral Ischemia-Reperfusion</title>
<p>We also examined the expression of inflammatory cytokines in the ischemic hemisphere of the WT and IRAK-M KO mice. At the transcriptional level, the expression levels of IL-1&#x03B2;, TNF-&#x03B1;, iNOS, COX-2, IL-10, and IL-6 were dramatically elevated in IRAK-M KO mice at 4 and 24 h after reperfusion (Figures <xref ref-type="fig" rid="F6">6A</xref>&#x2013;<xref ref-type="fig" rid="F6">L</xref>). Moreover, the protein expressions of COX-2, TNF-&#x03B1;, NLRP-3, and iNOS were also upregulated at both time points (Figures <xref ref-type="fig" rid="F7">7A,B,D,E</xref>). However, the protein expression of IL-10, an anti-inflammatory mediator, was markedly decreased contrary to its mRNA expression (Figure <xref ref-type="fig" rid="F7">7C</xref>).</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption><p>IRAK-M deletion further enhanced the mRNA levels of ischemia-induced inflammatory cytokines in mouse brains. <bold>(A</bold>&#x2013;<bold>L)</bold> Bar charts and linear graphs showing the mRNA levels of IL-1&#x03B2; <bold>(A,B)</bold>, TNF-&#x03B1; <bold>(C,D)</bold>, iNOS <bold>(E,F)</bold>, COX-2 <bold>(G,H),</bold> IL-10 <bold>(I,J),</bold> and IL-6 <bold>(K,L)</bold> in brain tissues at 4 h and 24 h after reperfusion in WT and KO mice. <italic>n</italic> = 5 per group. <sup>&#x2217;</sup><italic>P</italic> &#x003C; 0.05, <sup>&#x2217;&#x2217;</sup><italic>P</italic> &#x003C; 0.01 vs. WT group, <sup>#</sup><italic>P</italic> &#x003C; 0.05 vs. sham group.</p></caption>
<graphic xlink:href="fncel-12-00504-g006.tif"/>
</fig>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption><p>Effects of IRAK-M deletion on protein level of ischemia-induced inflammatory cytokines in mouse brains. <bold>(A&#x2013;E)</bold> Representative Western blot images of COX-2 <bold>(A)</bold>, TNF-&#x03B1; <bold>(B)</bold>, IL-10 <bold>(C)</bold>, NLRP-3 <bold>(D)</bold> and iNOS <bold>(E)</bold> at 4 h and 24 h after stroke in KO and WT mice. &#x03B2;-Actin was used as the loading control. <bold>(F)</bold> Representative Western blot images of NF-&#x03BA;B P65 in nuclei in the ischemic hemisphere of KO and WT mice at 24 h after reperfusion. The relative protein level was quantified and normalized to &#x03B2;-actin using ImageJ. <italic>n</italic> = 5 per group. <sup>&#x2217;</sup><italic>P</italic> &#x003C; 0.05, <sup>&#x2217;&#x2217;</sup><italic>P</italic> &#x003C; 0.01 vs. WT group, <sup>#</sup><italic>P</italic> &#x003C; 0.05 vs. sham group.</p></caption>
<graphic xlink:href="fncel-12-00504-g007.tif"/>
</fig>
<p>Those inflammatory mediators are either directly or indirectly triggered by NF-&#x03BA;B activation and inhibition of NF-&#x03BA;B activation is the critical step for the anti-inflammatory function of IRAK-M. We extracted proteins in nucleus to assess the localization of transcription factor P65 in the ischemic ipsilateral and contralateral hemisphere from different groups. Results in Figure <xref ref-type="fig" rid="F7">7F</xref> showed that the targeted deletion of IRAK-M induced more P65 nuclear translocation. In conclusion, these data suggest that, probably through inhibiting NF-&#x03BA;B signaling to alleviate inflammation, IRAK-M offers better neurovascular outcome in stroke mice.</p>
</sec>
<sec><title>IRAK-M Deficiency Was Associated With Increased Microglia in tMCAO Mice</title>
<p>Microglia is usually activated in the resident inflammatory environment and microglia leads to injury to BBB and exacerbates brain edema. To elucidate the effect of IRAK-M on microglia after stroke, we examined microglia activation in the cerebral cortex in the WT and <italic>Irak3</italic> KO mice at 24 h after reperfusion. As illustrated in Figure <xref ref-type="fig" rid="F8">8</xref>, the number of microglia, visualized by the staining of Iba1 antibody that specially binds to microglia common antigen, was significantly elevated at 24 h after reperfusion in KO mice compared with WT littermates (66.00 &#x00B1; 15.28 vs. 47.80 &#x00B1; 8.17), suggesting the increased microglia also participate in the exaggeration of neurovascular injury under the background of IRAK-M deficiency.</p>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption><p>IRAK-M deficiency is associated with the enhanced microglia in tMCAO mice. <bold>(A)</bold> Representative pictures of immunofluorescence staining with anti-Iba1 antibodies (green) in the peri-infarct cortex at 24 h after reperfusion. <bold>(B)</bold> The number of Iba1-positive cells were counted and shown in bar graph, Scale bar = 50 &#x03BC;m. <bold>(C)</bold> TTC staining of ischemic brain manifested the location where the corresponding images were obtained. The brain region in black boxes indicates the areas where the typical Iba-1-positive cells were observed. The number of Iba1-positive cells was counted using ImageJ. <italic>n</italic> = 5 per group. <sup>&#x2217;</sup><italic>P</italic> &#x003C; 0.05 vs. WT group, <sup>#</sup><italic>P</italic> &#x003C; 0.05 vs. sham group.</p></caption>
<graphic xlink:href="fncel-12-00504-g008.tif"/>
</fig>
</sec>
</sec>
<sec><title>Discussion</title>
<p>IRAK-M is an endogenous negative regulator of TLR signaling that prevents uncontrolled inflammation after tissue injury in multiple diseases. IRAK-M prevents dissociation of IRAK-1 and IRAK-4 from MyD88 and inhibits formation of IRAK-TRAF6 complexes and subsequent I&#x03BA;B degradation and NF-&#x03BA;B nuclear translocation. Nevertheless, its role in the cerebrovascular disorders is unclear. Here, we are the first to show that IRAK-M is increased in the infarcted brain, and its expression correlates with the increased HIF1-&#x03B1; expression. Deletion of <italic>Irak3</italic> aggravates functional deficits, cerebral infarct volume, brain edema, and causes hemorrhage transformation and BBB disruption. Meanwhile, we further demonstrate that IRAK-M deficiency offers increased expression of the mRNA and proteins of proinflammatory molecules, and enhances the activation of transcription factor NF-&#x03BA;B in ischemic brain regions. In summary, IRAK-M contributes to protect the brain from post-ischemic inflammatory response.</p>
<p>Ischemia-reperfusion that may contribute to the increased expression of IRAK-M has been, respectively, demonstrated in liver (<xref ref-type="bibr" rid="B18">Izuishi et al., 2006</xref>), heart (<xref ref-type="bibr" rid="B6">Chen et al., 2012</xref>), and brain (<xref ref-type="bibr" rid="B40">Wang et al., 2016</xref>). Compared with previous study at a single time point, the present study further revealed that the mRNA level of IRAK-M was dramatically upregulated at 1 h after cerebral ischemia reperfusion, and gradually downregulated in 24 h in the ischemic hemisphere, suggesting IRAK-M plays a role in acute stage of ischemic stroke. The effect of IRAK-M on infarct development hinges on their availability at early stage of ischemic stroke, consistent with the therapeutic window (&#x003C;4.5 h).</p>
<p>The expression of HIF-1&#x03B1; is a key event in the pathophysiology of cerebrovascular diseases (<xref ref-type="bibr" rid="B42">Wu et al., 2013</xref>; <xref ref-type="bibr" rid="B44">Zhang et al., 2017</xref>). In the early phase of ischemic stroke, exposure of mice brain to the hypoxic stimulus results in an induction of HIF-1&#x03B1; protein expression throughout the brain (<xref ref-type="bibr" rid="B48">Zhu et al., 2014</xref>). More importantly, HIF-1&#x03B1; is a transcription factor that induces IRAK-M expression in monocytes in the mice model of sepsis (<xref ref-type="bibr" rid="B33">Shalova et al., 2015</xref>). In line with this finding, we found that the increased IRAK-M in cerebral ischemic hemisphere was almost completely reversed by 2ME2, further indicating HIF-1&#x03B1; is involved in IRAK-M mRNA expression in stroke mice.</p>
<p>Brain edema and hemorrhagic transformation are two leading causes for death of stroke patients (<xref ref-type="bibr" rid="B3">Bounds et al., 1981</xref>). Swelling of ischemic tissue causes enlargement of the infarcted area and early stroke deterioration of patients (<xref ref-type="bibr" rid="B38">Toni et al., 1995</xref>). Hemorrhagic transformation is another serious complication that restricts the application of thrombolytic therapy and brings secondary injury to brain tissues (<xref ref-type="bibr" rid="B30">Mao et al., 2017</xref>). In the present study, we observed that the deletion of the IRAK-M results in the poorer prognosis of stroke exhibiting much more severe brain edema and higher incidence of hemorrhagic transformation. These evidences suggest that IRAK-M is associated with the pathophysiology of brain edema and hemorrhagic transformation accompanying stroke. Moreover, quick early induction in response to brain ischemia-reperfusion may be in connection with alleviating the brain damages, and may provide additional ischemic tolerance against following dramatic injurious stimuli (<xref ref-type="bibr" rid="B2">Amantea et al., 2015</xref>; <xref ref-type="bibr" rid="B40">Wang et al., 2016</xref>). Some protective approaches, such as pre- or post- conditioning and neuroprotectants, may also induce IRAK-M production and offer neurovascular protection in stroke (<xref ref-type="bibr" rid="B14">Gidday, 2006</xref>; <xref ref-type="bibr" rid="B18">Izuishi et al., 2006</xref>). These interesting hypotheses deserve further investigation.</p>
<p>Both the brain edema and hemorrhagic transformation are linked to the disruption of BBB. Alleviation of the load of resident neuroinflammation has well been recognized to reduce BBB permeability (<xref ref-type="bibr" rid="B7">da Fonseca et al., 2014</xref>). When ischemia begins, the cytokines, chemokines, and immediate early genes initiate the release of extracellular MMPs which attack the basal lamina around the capillary, rupture endothelial tight junctional proteins and thus allow the extravasation of plasma proteins and opening of BBB (<xref ref-type="bibr" rid="B32">Nissinen and Kahari, 2014</xref>; <xref ref-type="bibr" rid="B39">Vafadari et al., 2016</xref>; <xref ref-type="bibr" rid="B20">Kempuraj et al., 2017</xref>). In addition, as early as 2 h after reperfusion began in rat brain, the BBB leakage was found in non-infarct area (<xref ref-type="bibr" rid="B40">Wang et al., 2016</xref>). Considering the anti-inflammatory role of IRAK-M and the early induction during cerebral ischemia-reperfusion, it is highly suggested that BBB is an ideal protective target for IRAK-M. Here, the targeted deletion of IRAK-M contributed to increased pro-inflammatory cytokines, enhanced MMPs expression, and more extravasation of EB dye and IgG in the ipsilateral brain. Moreover, brain-derived MMP-2 and MMP-9 activated by ischemia are associate with hemorrhagic transformation (<xref ref-type="bibr" rid="B19">Jickling et al., 2014</xref>), partly explaining the high incidence of hemorrhage of stroke KO mice.</p>
<p>The mechanism of the anti-inflammatory function of IRAK-M has been investigated by several groups. One study shows that, via stabilizing MKP-1, IRAK-M can suppress p38 activation (<xref ref-type="bibr" rid="B34">Su et al., 2007</xref>), while p38 activation can lead to MMP-9 increase in astrocytes (<xref ref-type="bibr" rid="B15">Gorina et al., 2011</xref>), composing a possibility that p38 activation in IRAK-M-null mice upregulates MMP-9 in the experimental stroke. We are conducting more experiments to testify this hypothesis. Meanwhile, IRAK-M prevented dissociation of IRAK1 and IRAK4 from Myddosome, and prevented formation of IRAK-TRAF6 complexes, subsequently inhibiting I&#x03BA;B degradation and NF-&#x03BA;B nuclear translocation (<xref ref-type="bibr" rid="B1">Akira and Takeda, 2004</xref>). Besides, IRAK-M is also able to mediate TLR7-induced MEKK3-dependent second wave NF-&#x03BA;B activation via interaction with IRAK-2 and inhibits the production of cytokines and chemokines at translational levels (<xref ref-type="bibr" rid="B46">Zhou et al., 2013</xref>). These are partly verified by our findings revealing NF-&#x03BA;B activation and the expression of target genes, including TNF-&#x03B1;, IL-1&#x03B2;, IL-6, iNOS, and COX-2, in KO stroke mice.</p>
<p>Although the expressions of pro-inflammatory factors are regulated at multiple levels, inhibiting NF-&#x03BA;B-mediated gene expression is believed to be a critical approach to restrict inflammation and protect neurovascular injuries in stroke (<xref ref-type="bibr" rid="B24">Lanzillotta et al., 2015</xref>). Among them, TNF-&#x03B1;, IL-1&#x03B2; and IL-6, iNOS and COX-2 are all dynamically altered in different stages of brain ischemia-reperfusion, and they usually bring detrimental effect to brain and BBB (<xref ref-type="bibr" rid="B8">de Vries et al., 1996</xref>; <xref ref-type="bibr" rid="B23">Lambertsen et al., 2012</xref>; <xref ref-type="bibr" rid="B43">Yagami et al., 2016</xref>). Considering the anti-inflammatory role of IRAK-M and the upregulation of IRAK-M in the first 24 h, we selected 4 and 24 h time points to test the expression of cytokines. Our study clearly revealed that KO mice exhibited extremely elevation of TNF-&#x03B1;, IL-1&#x03B2;, and IL-6, suggesting that the absence of IRAK-M can exacerbate the brain tissue injury of stroke through releasing larger amounts of proinflammatory cytokines in the acute phase of stroke.</p>
<p>Collectively, IRAK-M is promptly induced in response to cerebral ischemia-reperfusion. Genetic null mice displayed more severe neurologic deficits, brain edema, hemorrhage, and BBB disruption in stroke model. The exacerbation is related to the pronounced activation of NF-&#x03BA;B-mediated expressions of inflammatory factors in genetic null mice. Our study firstly provides evidence revealing that the function of IRAK-M in the brain and IRAK-M is potential to facilitate the development of new pharmaceuticals that reduce neurovascular complications. It is worth investigating the role of IRAK-M in other brain disorders and whether it functions as a regulatory target for neuroprotective therapy.</p>
</sec>
<sec><title>Author Contributions</title>
<p>CL, YZ, MG, YH, and GL conducted the experiments. CW, ML, and SC performed statistical analysis. CL, YG, and SP wrote the manuscript. All authors read and approved the final manuscript.</p>
</sec>
<sec><title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p><bold>Funding.</bold> This work was supported by the Natural Science Foundation of Guangdong Province of China (Grant No. 2017A030313622), the Science and Technology Planning Project of Guangdong Province of China (Grant No. 2016A020215113), and the Science and Technology Program of Guangzhou of China (Grant No. 201804010446).</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akira</surname> <given-names>S.</given-names></name> <name><surname>Takeda</surname> <given-names>K.</given-names></name></person-group> (<year>2004</year>). <article-title>Toll-like receptor signalling.</article-title> <source><italic>Nat. Rev. Immunol.</italic></source> <volume>4</volume> <fpage>499</fpage>&#x2013;<lpage>511</lpage>. <pub-id pub-id-type="doi">10.1038/nri1391</pub-id> <pub-id pub-id-type="pmid">15229469</pub-id></citation></ref>
<ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amantea</surname> <given-names>D.</given-names></name> <name><surname>Micieli</surname> <given-names>G.</given-names></name> <name><surname>Tassorelli</surname> <given-names>C.</given-names></name> <name><surname>Cuartero</surname> <given-names>M. I.</given-names></name> <name><surname>Ballesteros</surname> <given-names>I.</given-names></name> <name><surname>Certo</surname> <given-names>M.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Rational modulation of the innate immune system for neuroprotection in ischemic stroke.</article-title> <source><italic>Front. Neurosci.</italic></source> <volume>9</volume>:<issue>147</issue>. <pub-id pub-id-type="doi">10.3389/fnins.2015.00147</pub-id> <pub-id pub-id-type="pmid">25972779</pub-id></citation></ref>
<ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bounds</surname> <given-names>J. V.</given-names></name> <name><surname>Wiebers</surname> <given-names>D. O.</given-names></name> <name><surname>Whisnant</surname> <given-names>J. P.</given-names></name> <name><surname>Okazaki</surname> <given-names>H.</given-names></name></person-group> (<year>1981</year>). <article-title>Mechanisms and timing of deaths from cerebral infarction.</article-title> <source><italic>Stroke</italic></source> <volume>12</volume> <fpage>474</fpage>&#x2013;<lpage>477</lpage>. <pub-id pub-id-type="doi">10.1161/01.str.12.4.474</pub-id></citation></ref>
<ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Caso</surname> <given-names>J. R.</given-names></name> <name><surname>Pradillo</surname> <given-names>J. M.</given-names></name> <name><surname>Hurtado</surname> <given-names>O.</given-names></name> <name><surname>Lorenzo</surname> <given-names>P.</given-names></name> <name><surname>Moro</surname> <given-names>M. A.</given-names></name> <name><surname>Lizasoain</surname> <given-names>I.</given-names></name></person-group> (<year>2007</year>). <article-title>Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke.</article-title> <source><italic>Circulation</italic></source> <volume>115</volume> <fpage>1599</fpage>&#x2013;<lpage>1608</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.603431</pub-id> <pub-id pub-id-type="pmid">17372179</pub-id></citation></ref>
<ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chavez</surname> <given-names>J. C.</given-names></name> <name><surname>LaManna</surname> <given-names>J. C.</given-names></name></person-group> (<year>2002</year>). <article-title>Activation of hypoxia-inducible factor-1 in the rat cerebral cortex after transient global ischemia: potential role of insulin-like growth factor-1.</article-title> <source><italic>J. Neurosci.</italic></source> <volume>22</volume> <fpage>8922</fpage>&#x2013;<lpage>8931</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.22-20-08922.2002</pub-id> <pub-id pub-id-type="pmid">12388599</pub-id></citation></ref>
<ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>W.</given-names></name> <name><surname>Saxena</surname> <given-names>A.</given-names></name> <name><surname>Li</surname> <given-names>N.</given-names></name> <name><surname>Sun</surname> <given-names>J.</given-names></name> <name><surname>Gupta</surname> <given-names>A.</given-names></name> <name><surname>Lee</surname> <given-names>D. W.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Endogenous IRAK-M attenuates postinfarction remodeling through effects on macrophages and fibroblasts.</article-title> <source><italic>Arterioscler. Thromb. Vasc. Biol.</italic></source> <volume>32</volume> <fpage>2598</fpage>&#x2013;<lpage>2608</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.112.300310</pub-id> <pub-id pub-id-type="pmid">22995519</pub-id></citation></ref>
<ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>da Fonseca</surname> <given-names>A. C.</given-names></name> <name><surname>Matias</surname> <given-names>D.</given-names></name> <name><surname>Garcia</surname> <given-names>C.</given-names></name> <name><surname>Amaral</surname> <given-names>R.</given-names></name> <name><surname>Geraldo</surname> <given-names>L. H.</given-names></name> <name><surname>Freitas</surname> <given-names>C.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>The impact of microglial activation on blood-brain barrier in brain diseases.</article-title> <source><italic>Front. Cell Neurosci.</italic></source> <volume>8</volume>:<issue>362</issue>. <pub-id pub-id-type="doi">10.3389/fncel.2014.00362</pub-id></citation></ref>
<ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Vries</surname> <given-names>H. E.</given-names></name> <name><surname>Blom-Roosemalen</surname> <given-names>M. C.</given-names></name> <name><surname>van Oosten</surname> <given-names>M.</given-names></name> <name><surname>de Boer</surname> <given-names>A. G.</given-names></name> <name><surname>van Berkel</surname> <given-names>T. J.</given-names></name> <name><surname>Breimer</surname> <given-names>D. D.</given-names></name><etal/></person-group> (<year>1996</year>). <article-title>The influence of cytokines on the integrity of the blood-brain barrier in vitro.</article-title> <source><italic>J. Neuroimmunol.</italic></source> <volume>64</volume> <fpage>37</fpage>&#x2013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1016/0165-5728(95)00148-4</pub-id></citation></ref>
<ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname> <given-names>L.</given-names></name> <name><surname>Wang</surname> <given-names>C.</given-names></name> <name><surname>Spencer</surname> <given-names>E.</given-names></name> <name><surname>Yang</surname> <given-names>L.</given-names></name> <name><surname>Braun</surname> <given-names>A.</given-names></name> <name><surname>You</surname> <given-names>J.</given-names></name><etal/></person-group> (<year>2000</year>). <article-title>Activation of the I&#x03BA;B Kinase Complex by TRAF6 Requires a Dimeric Ubiquitin-Conjugating Enzyme Complex and a Unique Polyubiquitin Chain.</article-title> <source><italic>Cell</italic></source> <volume>103</volume> <fpage>351</fpage>&#x2013;<lpage>361</lpage>. <pub-id pub-id-type="doi">10.1016/s0092-8674(00)00126-4</pub-id></citation></ref>
<ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Denorme</surname> <given-names>F.</given-names></name> <name><surname>Wyseure</surname> <given-names>T.</given-names></name> <name><surname>Peeters</surname> <given-names>M.</given-names></name> <name><surname>Vandeputte</surname> <given-names>N.</given-names></name> <name><surname>Gils</surname> <given-names>A.</given-names></name> <name><surname>Deckmyn</surname> <given-names>H.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Inhibition of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 reduces ischemic brain damage in mice.</article-title> <source><italic>Stroke</italic></source> <volume>47</volume> <fpage>2419</fpage>&#x2013;<lpage>2422</lpage>. <pub-id pub-id-type="doi">10.1161/STROKEAHA.116.014091</pub-id> <pub-id pub-id-type="pmid">27470988</pub-id></citation></ref>
<ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eltzschig</surname> <given-names>H. K.</given-names></name> <name><surname>Eckle</surname> <given-names>T.</given-names></name></person-group> (<year>2011</year>). <article-title>Ischemia and reperfusion&#x2013;from mechanism to translation.</article-title> <source><italic>Nat. Med.</italic></source> <volume>17</volume> <fpage>1391</fpage>&#x2013;<lpage>1401</lpage>. <pub-id pub-id-type="doi">10.1038/nm.2507</pub-id> <pub-id pub-id-type="pmid">22064429</pub-id></citation></ref>
<ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname> <given-names>Y.</given-names></name> <name><surname>Fang</surname> <given-names>X.</given-names></name> <name><surname>Tong</surname> <given-names>Y.</given-names></name> <name><surname>Liu</surname> <given-names>Y.</given-names></name> <name><surname>Zhang</surname> <given-names>B.</given-names></name></person-group> (<year>2009</year>). <article-title>TLR4-mediated MyD88-dependent signaling pathway is activated by cerebral ischemia-reperfusion in cortex in mice.</article-title> <source><italic>Biomed. Pharmacother.</italic></source> <volume>63</volume> <fpage>442</fpage>&#x2013;<lpage>450</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2008.06.028</pub-id> <pub-id pub-id-type="pmid">18804339</pub-id></citation></ref>
<ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Bonilla</surname> <given-names>L.</given-names></name> <name><surname>Benakis</surname> <given-names>C.</given-names></name> <name><surname>Moore</surname> <given-names>J.</given-names></name> <name><surname>Iadecola</surname> <given-names>C.</given-names></name> <name><surname>Anrather</surname> <given-names>J.</given-names></name></person-group> (<year>2014</year>). <article-title>Immune mechanisms in cerebral ischemic tolerance.</article-title> <source><italic>Front. Neurosci.</italic></source> <volume>8</volume>:<issue>44</issue>. <pub-id pub-id-type="doi">10.3389/fnins.2014.00044</pub-id></citation></ref>
<ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gidday</surname> <given-names>J. M.</given-names></name></person-group> (<year>2006</year>). <article-title>Cerebral preconditioning and ischaemic tolerance.</article-title> <source><italic>Nat. Rev. Neurosci.</italic></source> <volume>7</volume> <fpage>437</fpage>&#x2013;<lpage>448</lpage>. <pub-id pub-id-type="doi">10.1038/nrn1927</pub-id> <pub-id pub-id-type="pmid">16715053</pub-id></citation></ref>
<ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gorina</surname> <given-names>R.</given-names></name> <name><surname>Font-Nieves</surname> <given-names>M.</given-names></name> <name><surname>Marquez-Kisinousky</surname> <given-names>L.</given-names></name> <name><surname>Santalucia</surname> <given-names>T.</given-names></name> <name><surname>Planas</surname> <given-names>A. M.</given-names></name></person-group> (<year>2011</year>). <article-title>Astrocyte TLR4 activation induces a proinflammatory environment through the interplay between MyD88-dependent NFkappaB signaling, MAPK, and Jak1/Stat1 pathways.</article-title> <source><italic>Glia</italic></source> <volume>59</volume> <fpage>242</fpage>&#x2013;<lpage>255</lpage>. <pub-id pub-id-type="doi">10.1002/glia.21094</pub-id> <pub-id pub-id-type="pmid">21125645</pub-id></citation></ref>
<ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname> <given-names>Y.</given-names></name> <name><surname>Chen</surname> <given-names>J.</given-names></name> <name><surname>Shen</surname> <given-names>J.</given-names></name></person-group> (<year>2014</year>). <article-title>Herbal medicines for ischemic stroke: combating inflammation as therapeutic targets.</article-title> <source><italic>J. Neuroimmune. Pharmacol.</italic></source> <volume>9</volume> <fpage>313</fpage>&#x2013;<lpage>339</lpage>. <pub-id pub-id-type="doi">10.1007/s11481-014-9525-5</pub-id> <pub-id pub-id-type="pmid">24562591</pub-id></citation></ref>
<ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iadecola</surname> <given-names>C.</given-names></name> <name><surname>Anrather</surname> <given-names>J.</given-names></name></person-group> (<year>2011</year>). <article-title>The immunology of stroke: from mechanisms to translation.</article-title> <source><italic>Nat. Med.</italic></source> <volume>17</volume> <fpage>796</fpage>&#x2013;<lpage>808</lpage>. <pub-id pub-id-type="doi">10.1038/nm.2399</pub-id> <pub-id pub-id-type="pmid">21738161</pub-id></citation></ref>
<ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Izuishi</surname> <given-names>K.</given-names></name> <name><surname>Tsung</surname> <given-names>A.</given-names></name> <name><surname>Jeyabalan</surname> <given-names>G.</given-names></name> <name><surname>Critchlow</surname> <given-names>N. D.</given-names></name> <name><surname>Li</surname> <given-names>J.</given-names></name> <name><surname>Tracey</surname> <given-names>K. J.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Cutting edge: high-mobility group box 1 preconditioning protects against liver ischemia-reperfusion injury.</article-title> <source><italic>J. Immunol.</italic></source> <volume>176</volume> <fpage>7154</fpage>&#x2013;<lpage>7158</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.176.12.7154</pub-id> <pub-id pub-id-type="pmid">16751357</pub-id></citation></ref>
<ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jickling</surname> <given-names>G. C.</given-names></name> <name><surname>Liu</surname> <given-names>D.</given-names></name> <name><surname>Stamova</surname> <given-names>B.</given-names></name> <name><surname>Ander</surname> <given-names>B. P.</given-names></name> <name><surname>Zhan</surname> <given-names>X.</given-names></name> <name><surname>Lu</surname> <given-names>A.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Hemorrhagic transformation after ischemic stroke in animals and humans.</article-title> <source><italic>J. Cereb. Blood Flow Metab.</italic></source> <volume>34</volume> <fpage>185</fpage>&#x2013;<lpage>199</lpage>. <pub-id pub-id-type="doi">10.1038/jcbfm.2013.203</pub-id> <pub-id pub-id-type="pmid">24281743</pub-id></citation></ref>
<ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kempuraj</surname> <given-names>D.</given-names></name> <name><surname>Thangavel</surname> <given-names>R.</given-names></name> <name><surname>Selvakumar</surname> <given-names>G. P.</given-names></name> <name><surname>Zaheer</surname> <given-names>S.</given-names></name> <name><surname>Ahmed</surname> <given-names>M. E.</given-names></name> <name><surname>Raikwar</surname> <given-names>S. P.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Brain and peripheral atypical inflammatory mediators potentiate neuroinflammation and neurodegeneration.</article-title> <source><italic>Front. Cell Neurosci.</italic></source> <volume>11</volume>:<issue>216</issue>. <pub-id pub-id-type="doi">10.3389/fncel.2017.00216</pub-id> <pub-id pub-id-type="pmid">28790893</pub-id></citation></ref>
<ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname> <given-names>K.</given-names></name> <name><surname>Hernandez</surname> <given-names>L. D.</given-names></name> <name><surname>Gal&#x00E1;n</surname> <given-names>J. E.</given-names></name> <name><surname>Janeway</surname> <given-names>C. A.</given-names></name> <name><surname>Medzhitov</surname> <given-names>R.</given-names></name> <name><surname>Flavell</surname> <given-names>R. A.</given-names></name></person-group> (<year>2002</year>). <article-title>IRAK-M is a negative regulator of toll-like receptor signaling.</article-title> <source><italic>Cell</italic></source> <volume>110</volume> <fpage>191</fpage>&#x2013;<lpage>202</lpage>. <pub-id pub-id-type="doi">10.1016/s0092-8674(02)00827-9</pub-id></citation></ref>
<ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lakhan</surname> <given-names>S. E.</given-names></name> <name><surname>Kirchgessner</surname> <given-names>A.</given-names></name> <name><surname>Hofer</surname> <given-names>M.</given-names></name></person-group> (<year>2009</year>). <article-title>Inflammatory mechanisms in ischemic stroke: therapeutic approaches.</article-title> <source><italic>J. Transl. Med.</italic></source> <volume>7</volume>:<issue>97</issue>. <pub-id pub-id-type="doi">10.1186/1479-5876-7-97</pub-id> <pub-id pub-id-type="pmid">19919699</pub-id></citation></ref>
<ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lambertsen</surname> <given-names>K. L.</given-names></name> <name><surname>Biber</surname> <given-names>K.</given-names></name> <name><surname>Finsen</surname> <given-names>B.</given-names></name></person-group> (<year>2012</year>). <article-title>Inflammatory cytokines in experimental and human stroke.</article-title> <source><italic>J. Cereb. Blood Flow Metab.</italic></source> <volume>32</volume> <fpage>1677</fpage>&#x2013;<lpage>1698</lpage>. <pub-id pub-id-type="doi">10.1038/jcbfm.2012.88</pub-id> <pub-id pub-id-type="pmid">22739623</pub-id></citation></ref>
<ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lanzillotta</surname> <given-names>A.</given-names></name> <name><surname>Porrini</surname> <given-names>V.</given-names></name> <name><surname>Bellucci</surname> <given-names>A.</given-names></name> <name><surname>Benarese</surname> <given-names>M.</given-names></name> <name><surname>Branca</surname> <given-names>C.</given-names></name> <name><surname>Parrella</surname> <given-names>E.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>NF-kappaB in innate neuroprotection and age-related neurodegenerative diseases.</article-title> <source><italic>Front. Neurol.</italic></source> <volume>6</volume>:<issue>98</issue>. <pub-id pub-id-type="doi">10.3389/fneur.2015.00098</pub-id> <pub-id pub-id-type="pmid">26042083</pub-id></citation></ref>
<ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>H.</given-names></name> <name><surname>Cuartas</surname> <given-names>E.</given-names></name> <name><surname>Cui</surname> <given-names>W.</given-names></name> <name><surname>Choi</surname> <given-names>Y.</given-names></name> <name><surname>Crawford</surname> <given-names>T. D.</given-names></name> <name><surname>Ke</surname> <given-names>H. Z.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>IL-1 receptor-associated kinase M is a central regulator of osteoclast differentiation and activation.</article-title> <source><italic>J. Exp. Med.</italic></source> <volume>201</volume> <fpage>1169</fpage>&#x2013;<lpage>1177</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20041444</pub-id> <pub-id pub-id-type="pmid">15809356</pub-id></citation></ref>
<ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>M.</given-names></name> <name><surname>Chen</surname> <given-names>S.</given-names></name> <name><surname>Shi</surname> <given-names>X.</given-names></name> <name><surname>Lyu</surname> <given-names>C.</given-names></name> <name><surname>Zhang</surname> <given-names>Y.</given-names></name> <name><surname>Tan</surname> <given-names>M.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Cell permeable HMGB1-binding heptamer peptide ameliorates neurovascular complications associated with thrombolytic therapy in rats with transient ischemic stroke.</article-title> <source><italic>J. Neuroinflammation</italic></source> <volume>15</volume>:<issue>237</issue>. <pub-id pub-id-type="doi">10.1186/s12974-018-1267-5</pub-id> <pub-id pub-id-type="pmid">30139371</pub-id></citation></ref>
<ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liesz</surname> <given-names>A.</given-names></name> <name><surname>Dalpke</surname> <given-names>A.</given-names></name> <name><surname>Mracsko</surname> <given-names>E.</given-names></name> <name><surname>Antoine</surname> <given-names>D. J.</given-names></name> <name><surname>Roth</surname> <given-names>S.</given-names></name> <name><surname>Zhou</surname> <given-names>W.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>DAMP signaling is a key pathway inducing immune modulation after brain injury.</article-title> <source><italic>J. Neurosci.</italic></source> <volume>35</volume> <fpage>583</fpage>&#x2013;<lpage>598</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.2439-14.2015</pub-id> <pub-id pub-id-type="pmid">25589753</pub-id></citation></ref>
<ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>Z.</given-names></name> <name><surname>Huang</surname> <given-names>H.</given-names></name> <name><surname>Gu</surname> <given-names>Y.</given-names></name> <name><surname>Huang</surname> <given-names>K.</given-names></name> <name><surname>Hu</surname> <given-names>Y.</given-names></name> <name><surname>Ji</surname> <given-names>Z.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Glibenclamide ameliorates cerebral edema and improves outcomes in a rat model of status epilepticus.</article-title> <source><italic>Neuropharmacology</italic></source> <volume>121</volume> <fpage>1</fpage>&#x2013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2017.04.016</pub-id> <pub-id pub-id-type="pmid">28412320</pub-id></citation></ref>
<ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>G.</given-names></name> <name><surname>Park</surname> <given-names>Y. J.</given-names></name> <name><surname>Abraham</surname> <given-names>E.</given-names></name></person-group> (<year>2008</year>). <article-title>Interleukin-1 receptor-associated kinase (IRAK) -1-mediated NF-kappaB activation requires cytosolic and nuclear activity.</article-title> <source><italic>FASEB J.</italic></source> <volume>22</volume> <fpage>2285</fpage>&#x2013;<lpage>2296</lpage>. <pub-id pub-id-type="doi">10.1096/fj.07-101816</pub-id> <pub-id pub-id-type="pmid">18276832</pub-id></citation></ref>
<ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname> <given-names>L.</given-names></name> <name><surname>Li</surname> <given-names>P.</given-names></name> <name><surname>Zhu</surname> <given-names>W.</given-names></name> <name><surname>Cai</surname> <given-names>W.</given-names></name> <name><surname>Liu</surname> <given-names>Z.</given-names></name> <name><surname>Wang</surname> <given-names>Y.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Regulatory T cells ameliorate tissue plasminogen activator-induced brain haemorrhage after stroke.</article-title> <source><italic>Brain</italic></source> <volume>140</volume> <fpage>1914</fpage>&#x2013;<lpage>1931</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awx111</pub-id> <pub-id pub-id-type="pmid">28535201</pub-id></citation></ref>
<ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nechama</surname> <given-names>M.</given-names></name> <name><surname>Kwon</surname> <given-names>J.</given-names></name> <name><surname>Wei</surname> <given-names>S.</given-names></name> <name><surname>Kyi</surname> <given-names>A. T.</given-names></name> <name><surname>Welner</surname> <given-names>R. S.</given-names></name> <name><surname>Ben-Dov</surname> <given-names>I. Z.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>The IL-33-PIN1-IRAK-M axis is critical for type 2 immunity in IL-33-induced allergic airway inflammation.</article-title> <source><italic>Nat. Commun.</italic></source> <volume>9</volume>:<issue>1603</issue>. <pub-id pub-id-type="doi">10.1038/s41467-018-03886-6</pub-id> <pub-id pub-id-type="pmid">29686383</pub-id></citation></ref>
<ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nissinen</surname> <given-names>L.</given-names></name> <name><surname>Kahari</surname> <given-names>V. M.</given-names></name></person-group> (<year>2014</year>). <article-title>Matrix metalloproteinases in inflammation.</article-title> <source><italic>Biochim. Biophys. Acta</italic></source> <volume>1840</volume> <fpage>2571</fpage>&#x2013;<lpage>2580</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbagen.2014.03.007</pub-id> <pub-id pub-id-type="pmid">24631662</pub-id></citation></ref>
<ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shalova</surname> <given-names>I. N.</given-names></name> <name><surname>Lim</surname> <given-names>J. Y.</given-names></name> <name><surname>Chittezhath</surname> <given-names>M.</given-names></name> <name><surname>Zinkernagel</surname> <given-names>A. S.</given-names></name> <name><surname>Beasley</surname> <given-names>F.</given-names></name> <name><surname>Hernandez-Jimenez</surname> <given-names>E.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Human monocytes undergo functional re-programming during sepsis mediated by hypoxia-inducible factor-1alpha.</article-title> <source><italic>Immunity</italic></source> <volume>42</volume> <fpage>484</fpage>&#x2013;<lpage>498</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2015.02.001</pub-id> <pub-id pub-id-type="pmid">25746953</pub-id></citation></ref>
<ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Su</surname> <given-names>J.</given-names></name> <name><surname>Xie</surname> <given-names>Q.</given-names></name> <name><surname>Wilson</surname> <given-names>I.</given-names></name> <name><surname>Li</surname> <given-names>L.</given-names></name></person-group> (<year>2007</year>). <article-title>Differential regulation and role of interleukin-1 receptor associated kinase-M in innate immunity signaling.</article-title> <source><italic>Cell. Signal.</italic></source> <volume>19</volume> <fpage>1596</fpage>&#x2013;<lpage>1601</lpage>. <pub-id pub-id-type="doi">10.1016/j.cellsig.2007.02.009</pub-id> <pub-id pub-id-type="pmid">17379480</pub-id></citation></ref>
<ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Su</surname> <given-names>J.</given-names></name> <name><surname>Zhang</surname> <given-names>T.</given-names></name> <name><surname>Tyson</surname> <given-names>J.</given-names></name> <name><surname>Li</surname> <given-names>L.</given-names></name></person-group> (<year>2009</year>). <article-title>The interleukin-1 receptor-associated kinase M selectively inhibits the alternative, instead of the classical NFkappaB pathway.</article-title> <source><italic>J. Innate Immun.</italic></source> <volume>1</volume> <fpage>164</fpage>&#x2013;<lpage>174</lpage>. <pub-id pub-id-type="doi">10.1159/000158541</pub-id> <pub-id pub-id-type="pmid">19809574</pub-id></citation></ref>
<ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname> <given-names>Q.</given-names></name> <name><surname>Majewska-Szczepanik</surname> <given-names>M.</given-names></name> <name><surname>Zhang</surname> <given-names>X.</given-names></name> <name><surname>Szczepanik</surname> <given-names>M.</given-names></name> <name><surname>Zhou</surname> <given-names>Z.</given-names></name> <name><surname>Wong</surname> <given-names>F. S.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>IRAK-M deficiency promotes the development of type 1 diabetes in NOD mice.</article-title> <source><italic>Diabetes Metab. Res. Rev.</italic></source> <volume>63</volume> <fpage>2761</fpage>&#x2013;<lpage>2775</lpage>. <pub-id pub-id-type="doi">10.2337/db13-1504</pub-id> <pub-id pub-id-type="pmid">24696448</pub-id></citation></ref>
<ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname> <given-names>S. C.</given-names></name> <name><surname>Arumugam</surname> <given-names>T. V.</given-names></name> <name><surname>Xu</surname> <given-names>X.</given-names></name> <name><surname>Cheng</surname> <given-names>A.</given-names></name> <name><surname>Mughal</surname> <given-names>M. R.</given-names></name> <name><surname>Jo</surname> <given-names>D. G.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits.</article-title> <source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source> <volume>104</volume> <fpage>13798</fpage>&#x2013;<lpage>13803</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0702553104</pub-id> <pub-id pub-id-type="pmid">17693552</pub-id></citation></ref>
<ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Toni</surname> <given-names>D.</given-names></name> <name><surname>Fiorelli</surname> <given-names>M.</given-names></name> <name><surname>Gentile</surname> <given-names>M.</given-names></name> <name><surname>Bastianello</surname> <given-names>S.</given-names></name> <name><surname>Sacchetti</surname> <given-names>M. L.</given-names></name> <name><surname>Argentino</surname> <given-names>C.</given-names></name><etal/></person-group> (<year>1995</year>). <article-title>Progressing neurological deficit secondary to acute ischemic stroke. A study on predictability, pathogenesis, and prognosis.</article-title> <source><italic>Arch. Neurol.</italic></source> <volume>52</volume> <fpage>670</fpage>&#x2013;<lpage>675</lpage>. <pub-id pub-id-type="doi">10.1001/archneur.1995.00540310040014</pub-id> <pub-id pub-id-type="pmid">7619022</pub-id></citation></ref>
<ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vafadari</surname> <given-names>B.</given-names></name> <name><surname>Salamian</surname> <given-names>A.</given-names></name> <name><surname>Kaczmarek</surname> <given-names>L.</given-names></name></person-group> (<year>2016</year>). <article-title>MMP-9 in translation: from molecule to brain physiology, pathology, and therapy.</article-title> <source><italic>J. Neurochem.</italic></source> <volume>139</volume><issue>(Suppl. 2)</issue>, <fpage>91</fpage>&#x2013;<lpage>114</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.13415</pub-id> <pub-id pub-id-type="pmid">26525923</pub-id></citation></ref>
<ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>C.</given-names></name> <name><surname>Liu</surname> <given-names>X. X.</given-names></name> <name><surname>Huang</surname> <given-names>K. B.</given-names></name> <name><surname>Yin</surname> <given-names>S. B.</given-names></name> <name><surname>Wei</surname> <given-names>J. J.</given-names></name> <name><surname>Hu</surname> <given-names>Y. F.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Preconditioning with recombinant high-mobility group box 1 induces ischemic tolerance in a rat model of focal cerebral ischemia-reperfusion.</article-title> <source><italic>J. Neurochem.</italic></source> <volume>137</volume> <fpage>576</fpage>&#x2013;<lpage>588</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.13611</pub-id> <pub-id pub-id-type="pmid">26991073</pub-id></citation></ref>
<ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weersma</surname> <given-names>R. K.</given-names></name> <name><surname>Oostenbrug</surname> <given-names>L. E.</given-names></name> <name><surname>Nolte</surname> <given-names>I. M.</given-names></name> <name><surname>Van Der Steege</surname> <given-names>G.</given-names></name> <name><surname>Oosterom</surname> <given-names>E.</given-names></name> <name><surname>Van Dullemen</surname> <given-names>H. M.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Association of interleukin-1 receptor-associated kinase M (IRAK-M) and inflammatory bowel diseases.</article-title> <source><italic>Scand. J. Gastroenterol.</italic></source> <volume>42</volume> <fpage>827</fpage>&#x2013;<lpage>833</lpage>. <pub-id pub-id-type="doi">10.1080/00365520601114024</pub-id> <pub-id pub-id-type="pmid">17558906</pub-id></citation></ref>
<ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>C.</given-names></name> <name><surname>Hu</surname> <given-names>Q.</given-names></name> <name><surname>Chen</surname> <given-names>J.</given-names></name> <name><surname>Yan</surname> <given-names>F.</given-names></name> <name><surname>Li</surname> <given-names>J.</given-names></name> <name><surname>Wang</surname> <given-names>L.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Inhibiting HIF-1alpha by 2ME2 ameliorates early brain injury after experimental subarachnoid hemorrhage in rats.</article-title> <source><italic>Biochem. Biophys. Res. Commun.</italic></source> <volume>437</volume> <fpage>469</fpage>&#x2013;<lpage>474</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2013.06.107</pub-id> <pub-id pub-id-type="pmid">23850688</pub-id></citation></ref>
<ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yagami</surname> <given-names>T.</given-names></name> <name><surname>Koma</surname> <given-names>H.</given-names></name> <name><surname>Yamamoto</surname> <given-names>Y.</given-names></name></person-group> (<year>2016</year>). <article-title>Pathophysiological roles of cyclooxygenases and prostaglandins in the central nervous system.</article-title> <source><italic>Mol. Neurobiol.</italic></source> <volume>53</volume> <fpage>4754</fpage>&#x2013;<lpage>4771</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-015-9355-3</pub-id> <pub-id pub-id-type="pmid">26328537</pub-id></citation></ref>
<ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>Y.</given-names></name> <name><surname>Yang</surname> <given-names>K.</given-names></name> <name><surname>Wang</surname> <given-names>T.</given-names></name> <name><surname>Li</surname> <given-names>W.</given-names></name> <name><surname>Jin</surname> <given-names>X.</given-names></name> <name><surname>Liu</surname> <given-names>W.</given-names></name></person-group> (<year>2017</year>). <article-title>Nrdp1 increases ischemia induced primary rat cerebral cortical neurons and pheochromocytoma cells apoptosis via downregulation of HIF-1&#x03B1; protein.</article-title> <source><italic>Front. Cell. Neurosci.</italic></source> <volume>11</volume>:<issue>293</issue>. <pub-id pub-id-type="doi">10.3389/fncel.2017.00293</pub-id></citation></ref>
<ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>H.</given-names></name> <name><surname>Chen</surname> <given-names>Z.</given-names></name> <name><surname>Xie</surname> <given-names>L. J.</given-names></name> <name><surname>Liu</surname> <given-names>G. F.</given-names></name></person-group> (<year>2018</year>). <article-title>Suppression of TLR4/NF-kappaB signaling pathway improves cerebral ischemia-reperfusion injury in rats.</article-title> <source><italic>Mol. Neurobiol.</italic></source> <volume>55</volume> <fpage>4311</fpage>&#x2013;<lpage>4319</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-017-0552-0</pub-id> <pub-id pub-id-type="pmid">28624894</pub-id></citation></ref>
<ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>H.</given-names></name> <name><surname>Yu</surname> <given-names>M.</given-names></name> <name><surname>Fukuda</surname> <given-names>K.</given-names></name> <name><surname>Im</surname> <given-names>J.</given-names></name> <name><surname>Yao</surname> <given-names>P.</given-names></name> <name><surname>Cui</surname> <given-names>W.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>IRAK-M mediates Toll-like receptor/IL-1R-induced NFkappaB activation and cytokine production.</article-title> <source><italic>EMBO J.</italic></source> <volume>32</volume> <fpage>583</fpage>&#x2013;<lpage>596</lpage>. <pub-id pub-id-type="doi">10.1038/emboj.2013.2</pub-id> <pub-id pub-id-type="pmid">23376919</pub-id></citation></ref>
<ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>H.</given-names></name> <name><surname>Yu</surname> <given-names>M.</given-names></name> <name><surname>Zhao</surname> <given-names>J.</given-names></name> <name><surname>Martin</surname> <given-names>B. N.</given-names></name> <name><surname>Roychowdhury</surname> <given-names>S.</given-names></name> <name><surname>McMullen</surname> <given-names>M. R.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>IRAKM-Mincle axis links cell death to inflammation: Pathophysiological implications for chronic alcoholic liver disease.</article-title> <source><italic>Hepatology</italic></source> <volume>64</volume> <fpage>1978</fpage>&#x2013;<lpage>1993</lpage>. <pub-id pub-id-type="doi">10.1002/hep.28811</pub-id> <pub-id pub-id-type="pmid">27628766</pub-id></citation></ref>
<ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>T.</given-names></name> <name><surname>Zhan</surname> <given-names>L.</given-names></name> <name><surname>Liang</surname> <given-names>D.</given-names></name> <name><surname>Hu</surname> <given-names>J.</given-names></name> <name><surname>Lu</surname> <given-names>Z.</given-names></name> <name><surname>Zhu</surname> <given-names>X.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Hypoxia-inducible factor 1alpha mediates neuroprotection of hypoxic postconditioning against global cerebral ischemia.</article-title> <source><italic>J. Neuropathol. Exp. Neurol.</italic></source> <volume>73</volume> <fpage>975</fpage>&#x2013;<lpage>986</lpage>. <pub-id pub-id-type="doi">10.1097/NEN.0000000000000118</pub-id> <pub-id pub-id-type="pmid">25192050</pub-id></citation></ref>
</ref-list>
<glossary>
<title>Abbreviations</title>
<def-list id="DL1">
<def-item>
<term>BBB</term>
<def>
<p>blood&#x2013;brain barrier</p>
</def>
</def-item>
<def-item>
<term>CBF</term>
<def>
<p>cerebral blood flow</p>
</def>
</def-item>
<def-item>
<term>DAPI</term>
<def>
<p>40,6-diamidino-2-phenylindole</p>
</def>
</def-item>
<def-item>
<term>EB</term>
<def>
<p>Evans blue</p>
</def>
</def-item>
<def-item>
<term>HIF</term>
<def>
<p>hypoxia-inducible factor</p>
</def>
</def-item>
<def-item>
<term>IKK</term>
<def>
<p>I&#x03BA;B kinase</p>
</def>
</def-item>
<def-item>
<term>IRAK-M</term>
<def>
<p>interleukin-1 receptor-associated kinase</p>
</def>
</def-item>
<def-item>
<term>KO</term>
<def>
<p>knockout</p>
</def>
</def-item>
<def-item>
<term>MAPK</term>
<def>
<p>mitogen-activated protein kinase</p>
</def>
</def-item>
<def-item>
<term>MCA</term>
<def>
<p>middle cerebral artery</p>
</def>
</def-item>
<def-item>
<term>MEKK</term>
<def>
<p>mitogen-activated protein kinase kinase</p>
</def>
</def-item>
<def-item>
<term>MMPs</term>
<def>
<p>metal metalloproteinases</p>
</def>
</def-item>
<def-item>
<term>MyD88</term>
<def>
<p>myeloid differentiation primary response 88</p>
</def>
</def-item>
<def-item>
<term>NF-&#x03BA;B</term>
<def>
<p>nuclear factor-&#x03BA;B</p>
</def>
</def-item>
<def-item>
<term>PRRs</term>
<def>
<p>pathogen recognition receptors</p>
</def>
</def-item>
<def-item>
<term>SPF</term>
<def>
<p>specific pathogen-free</p>
</def>
</def-item>
<def-item>
<term>tMCAO</term>
<def>
<p>transient middle cerebral artery occlusion</p>
</def>
</def-item>
<def-item>
<term>TLRs</term>
<def>
<p>toll-like receptors</p>
</def>
</def-item>
<def-item>
<term>TTC</term>
<def>
<p>2,3,5-triphenyltetrazolium chloride</p>
</def>
</def-item>
<def-item>
<term>WT</term>
<def>
<p>wild-type</p>
</def>
</def-item>
</def-list>
</glossary>
</back>
</article>